Distinct Hepatitis B and HIV co-infected populations in Canada.
Hepatitis B
North America
epidemiology
human Immunodeficiency Virus
liver disease
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
22
07
2020
revised:
02
11
2020
accepted:
18
11
2020
pubmed:
12
12
2020
medline:
1
9
2021
entrez:
11
12
2020
Statut:
ppublish
Résumé
Due to shared modes of exposure, HIV-HBV co-infection is common worldwide. Increased knowledge of the demographic and clinical characteristics of the co-infected population will allow us to optimize our approach to management of both infections in clinical practice. The Canadian Hepatitis B Network Cohort was utilized to conduct a cross-sectional evaluation of the demographic, biochemical, fibrotic and treatment characteristics of HIV-HBV patients and a comparator HBV group. From a total of 5996 HBV-infected patients, 335 HIV-HBV patients were identified. HIV-HBV patients were characterized by older median age, higher male and lower Asian proportion, more advanced fibrosis and higher anti-HBV therapy use (91% vs. 30%) than the HBV-positive / HIV seronegative comparator group. A history of reported high-risk exposure activities (drug use, high-risk sexual contact) was more common in HIV-HBV patients. HIV-HBV patients with reported high-risk exposure activities had higher male proportion, more Caucasian ethnicity and higher prevalence of cirrhosis than HIV-HBV patients born in an endemic country. In the main cohort, age ≥60 years, male sex, elevated ALT, the presence of comorbidity and HCV seropositivity were independent predictors of significant fibrosis. HIV seropositivity was not an independent predictor of advanced fibrosis (adj OR 0.75 [95%CI: 0.34-1.67]). In conclusion, Canadian co-infected patients differed considerably from those with mono-infection. Furthermore, HIV-HBV-infected patients who report high-risk behaviours and those born in endemic countries represent two distinct subpopulations, which should be considered when engaging these patients in care.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
517-527Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212-2219.
MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015;5(5):a021410.
UNAIDS. Global HIV & AIDS Statistics - 2019 Fact Sheet. Available at: https://www.unaids.org/en/resources/fact-sheet. Accessed February 24.
Pittman C, Plitt S, Birse T, et al. Prevalence and correlates of HIV and hepatitis B virus coinfection in Northern Alberta. Can J Infect Dis Med Microbiol. 2014;25(1):e8-e13.
Gillis J, Cooper C, Rourke S, et al. Impact of hepatitis B and C co-infection on health-related quality of life in HIV positive individuals. Qual Life Res. 2013;22(7):1525-1535.
Spradling P, Richardson J, Buchacz K, Moorman A, Brooks J, Investigators HOS. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007. J Viral Hepatitis. 2010;17(12):879-886.
Sterling RK, Wahed AS, King WC, et al. Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study. Am J Gastroenterol. 2019;114(5):746-757.
Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). The Lancet. 2002;360(9349):1921-1926.
Marin B, Thiébaut R, Bucher HC, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (London, England). 2009;23(13):1743.
Konopnicki D, Mocroft A, De Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. Aids. 2005;19(6):593-601.
Nikolopoulo GK, Paraskevis D, Hatzitheodorou E, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis. 2009;48(12):1763-1771.
Public Health Agency of Canada. Brief Report: Hepatitis B Infection in Canada. 2011.
Coffin CS, Ramji A, Cooper CL, et al. Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV Network. CMAJ Open. 2019;7(4):E610-E617.
Coffin CS, Osiowy C, Myers RP, Gill MJ. Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients. J Clin Virol. 2013;57(2):103-108.
Hull M, Shafran S, Wong A, et al. CIHR Canadian HIV Trials network coinfection and concurrent diseases core research group: 2016 updated Canadian HIV/Hepatitis C adult guidelines for management and treatment. Can J Infect Dis Med Microbiol. 2016;2016:4385643.
Boyd A, Bottero J, Miailhes P, et al. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study. J Int AIDS Soc. 2017;20(1):21426.
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335-352.
Hawkins C, Christian B, Fabian E, et al. Brief Report: HIV/HBV Coinfection is a Significant Risk Factor for Liver Fibrosis in Tanzanian HIV-Infected Adults. J Acquir Immune Defic Syndr. 2017;76(3):298-302.
Maponga TG, Andersson MI, van Rensburg CJ, et al. HBV and HIV viral load but not microbial translocation or immune activation are associated with liver fibrosis among patients in South Africa. BMC Infect Dis. 2018;18(1):214.
Audsley J, Seaberg EC, Sasadeusz J, et al. Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART. PLoS One. 2011;6(11):e26482.
Chang JJ, Sirivichayakul S, Avihingsanon A, et al. Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol. 2009;83(15):7649-7658.
Ryom L, Lundgren JD, De Wit S, et al. Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. AIDS. 2016;30(11):1731-1743.
Al-Mohri H, Cooper C, Murphy T, Klein M. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV medicine. 2005;6(6):375-378.
Wu SD, Wang JY, Li L. Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study. World J Gastroenterol. 2010;16(4):501-507.
Shaheen AAM, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: A systematic review. Hepatology. 2007;46(3):912-921.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546-1555.
Statistics Canada. Immigration and ethnocultural diversity: Key results from the 2016 Census. Available at: https://www150.statcan.gc.ca/n1/en/daily-quotidien/171025/dq171025b-eng.pdf?st=rRJWVNh7. Accessed February 24.
Osiowy C, Simons BC, Rempel JD. Distribution of viral hepatitis in indigenous populations of North America and the circumpolar Arctic. Antivir Ther 2013; 18(3 Pt B): 467-473.
Friedman MR, Wei C, Klem ML, Silvestre AJ, Markovic N, Stall R. HIV infection and sexual risk among men who have sex with men and women (MSMW): a systematic review and meta-analysis. PLoS One. 2014;9(1):e87139.
Inoue T, Tanaka Y. Hepatitis B virus and its sexually transmitted infection - an update. Microb Cell. 2016;3(9):420-437.
Coffin CS, Fung SK, Alvarez F, et al. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada. Can Liver J. 2018;1(4):156-217.
Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356(9244):1800-1805.
Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol. 2008;48(2):353-367.
Oh IS, Park SH. Immune-mediated Liver Injury in Hepatitis B Virus Infection. Immune Netw. 2015;15(4):191-198.
Kapoor N, Audsley J, Rupali P, et al. A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries. AIDS. 2019;33(7):1105-1115.
Edmunds WJ, Medley GF, Nokes DJ, O'Callaghan CJ, Whittle HC, Hall AJ. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect. 1996;117(2):313-325.
World Health Organization. Global Hepatitis Report 2017. Available at: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed February 24.